Marek Matus
University of Münster
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marek Matus.
Circulation | 2008
Bodo Levkau; Michael Schäfers; Jeremias Wohlschlaeger; Karin von Wnuck Lipinski; Petra Keul; Sven Hermann; Naomasa Kawaguchi; Paulus Kirchhof; Larissa Fabritz; Jörg Stypmann; Lars Stegger; Ulrich Flögel; J. Schrader; Jens W. Fischer; Patrick C.H. Hsieh; Yen-Ling Ou; Felix Mehrhof; Klaus Tiemann; Alexander Ghanem; Marek Matus; Joachim Neumann; Gerd Heusch; Kurt Werner Schmid; Edward M. Conway; Hideo Baba
Background— Survivin inhibits apoptosis and regulates cell division in many organs, but its function in the heart is unknown. Methods and Results— We show that cardiac-specific deletion of survivin resulted in premature cardiac death. The underlying cause was a dramatic reduction in total cardiomyocyte numbers as determined by a stereological method for quantification of cells per organ. The resulting increased hemodynamic load per cell led to progressive heart failure as assessed by echocardiography, magnetic resonance imaging, positron emission tomography, and invasive catheterization. The reduction in total cardiomyocyte number in α-myosin heavy chain (MHC)–survivin−/− mice was due to an ≈50% lower mitotic rate without increased apoptosis. This occurred at the expense of DNA accumulation because survivin-deficient cardiomyocytes displayed marked DNA polyploidy indicative of consecutive rounds of DNA replication without cell division. Survivin small interfering RNA knockdown in neonatal rat cardiomyocytes also led to polyploidization and cell cycle arrest without apoptosis. Adenoviral overexpression of survivin in cardiomyocytes inhibited doxorubicin-induced apoptosis, induced DNA synthesis, and promoted cell cycle progression. The phenotype of the αMHC-survivin−/− mice also allowed us to determine the minimum cardiomyocyte number sufficient for normal cardiac function. In human cardiomyopathy, survivin was potently induced in the failing heart and downregulated again after hemodynamic support by a left ventricular assist device. Its expression positively correlated with the mean cardiomyocyte DNA content. Conclusions— We suggest that the ontogenetically determined cardiomyocyte number may be an independent factor in the susceptibility to cardiac diseases. Through its profound impact on both cardiomyocyte replication and apoptosis, survivin may emerge as a promising new target for myocardial regeneration.
Journal of Biological Chemistry | 2005
Frank U. Müller; Geertje Lewin; Hideo A. Baba; Peter Boknik; Larissa Fabritz; Uwe Kirchhefer; Paulus Kirchhof; Karin Loser; Marek Matus; Joachim Neumann; Burkhard Riemann; Wilhelm Schmitz
The transcriptional activation mediated by cAMP-response element (CRE) and transcription factors of the CRE-binding protein (CREB)/CRE modulator (CREM) family represents an important mechanism of cAMP-dependent gene regulation possibly implicated in detrimental effects of chronic β-adrenergic stimulation in end-stage heart failure. We studied the cardiac role of CREM in transgenic mice with heart-directed expression of CREM-IbΔC-X, a human cardiac CREM isoform. Transgenic mice displayed atrial enlargement with atrial and ventricular hypertrophy, developed atrial fibrillation, and died prematurely. In vivo hemodynamic assessment revealed increased contractility of transgenic left ventricles probably due to a selective up-regulation of SERCA2, the cardiac Ca2+-ATPase of the sarcoplasmic reticulum. In transgenic ventricles, reduced phosphorylation of phospholamban and of the CREB was associated with increased activity of serine-threonine protein phosphatase 1. The density of β1-adrenoreceptor was increased, and messenger RNAs encoding transcription factor dHAND and small G-protein RhoB were decreased in transgenic hearts as compared with wild-type controls. Our results indicate that heart-directed expression of CREM-IbΔC-X leads to complex cardiac alterations, suggesting CREM as a central regulator of cardiac morphology, function, and gene expression.
The FASEB Journal | 2002
Frank U. Müller; Geertje Lewin; Marek Matus; Joachim Neumann; Burkhard Riemann; Joachim Wistuba; Günther Schütz; Wilhelm Schmitz
Congestive heart failure is the common endpoint of various cardiac diseases representing a leading cause of cardiovascular mortality in Western countries. Characteristic functional alterations of the failing heart are explained by expressional changes of myocardial regulatory proteins; however, little is known about underlying mechanisms regulating cardiac gene expression in the failing heart. Here, we address the specific role of transcription factor CREM for cardiac function in CREM mutant mice with complete inactivation of the CREM gene. We show that CREM mutant mice display distinct alterations of cardiac function resembling characteristic functional defects of the failing heart. Left ventricular hemodynamic assessment of CREM mutant mice revealed impairment of both cardiac contraction and relaxation in basal state, as well as a decreased responsiveness to β‐adrenergic stimulation. The diminished cardiac contractile performance was associated with a selective down‐regulation of β1‐adrenergic 2+ receptors and a decreased ventricular expression of SERCA, the Ca‐ATPase of the sarcoplasmic reticulum. The cardiac phenotype of CREM mutant mice provides the first evidence that CREM represents an important key regulator of cardiac gene expression, which is essential for normal left ventricular contractile performance and response to β‐adrenoreceptor stimulation.
Cardiovascular Research | 2008
Stephanie Grote-Wessels; Hideo Baba; Peter Boknik; Ali El-Armouche; Larissa Fabritz; Hans-Jörg Gillmann; Dana Kucerova; Marek Matus; Frank U. Müller; Joachim Neumann; Martina Schmitz; Frank Stümpel; Gregor Theilmeier; Jeremias Wohlschlaeger; Wilhelm Schmitz; Uwe Kirchhefer
AIMS The progression of human heart failure is associated with increased protein phosphatase 1 (PP1) activity, which leads to a higher dephosphorylation of cardiac regulatory proteins such as phospholamban. In this study, we tested the hypothesis whether the inhibitor-2 (I-2) of PP1 can mediate cardiac protection by inhibition of PP1 activity. METHODS AND RESULTS We induced pressure overload by transverse aortic constriction (TAC) for 28 days in transgenic (TG) mice with heart-directed overexpression of a constitutively active form of I-2 (TG(TAC)) and wild-type littermates (WT(TAC)). Both groups were compared with sham-operated mice. TAC treatment resulted in comparable ventricular hypertrophy in both groups. However, TG(TAC) exhibited a higher atrial mass and an enhanced ventricular mRNA expression of beta-myosin heavy chain. The increased afterload was associated with the development of focal fibrosis in TG. Consistent with signs of overt heart failure, fractional shortening and diastolic function were impaired in TG(TAC) as revealed by Doppler echocardiography. The contractility was reduced in catheterized banded TG mice, which is in line with a depressed shortening of isolated myocytes. This is due to profoundly abnormal cytosolic Ca(2+) transients and a reduced stimulation of phosphorylation of phospholamban (PLB)(Ser16) after TAC in TG mice. Moreover, administration of isoproterenol was followed by a blunted contractile response in isolated myocytes of TG(TAC) mice. CONCLUSION These results suggest that cardiac-specific overexpression of a constitutively active form of I-2 is deleterious for cardiac function under conditions of pressure overload. Thus, the long-term inhibition of PP1 by I-2 is not a therapeutic option in the treatment of heart failure.
Journal of Immunology | 2009
Martina Ahlmann; Georg Varga; Karsten Sturm; Ralph Lippe; Konrad Benedyk; Dorothee Viemann; Thomas Scholzen; Jan Ehrchen; Frank U. Müller; Matthias D. Seidl; Marek Matus; George C. Tsokos; J. Roth; Klaus Tenbrock
The cAMP response element modulator (CREM)α is a widely expressed transcriptional repressor that is important for the termination of the T cell immune response and contributes to the abnormal T cell function in patients with systemic lupus erythematosus. We present evidence that APCs of Crem−/− mice express increased amounts of the costimulatory molecule CD86 and induce enhanced Ag-dependent and Ag-independent T cell proliferation. Similarly, human APCs in which CREMα was selectively suppressed expressed more CD86 on the surface membrane. CREMα was found to bind to the CD86 promoter and suppressed its activity. Transfer of APCs from Crem−/− mice into naive mice facilitated a significantly stronger contact dermatitis response compared with mice into which APCs from Crem+/+ mice had been transferred. We conclude that CREMα is an important negative regulator of costimulation and APC-dependent T cell function both in vitro and in vivo.
Circulation | 2009
Geertje Lewin; Marek Matus; Abhijit Basu; Karin Frebel; Sebastian Pius Rohsbach; Andrej Safronenko; Matthias D. Seidl; Frank Stümpel; Igor B. Buchwalow; Simone König; Stefan Engelhardt; Martin J. Lohse; Wilhelm Schmitz; Frank Ulrich Müller
Background— Chronic stimulation of the &bgr;1-adrenoceptor (&bgr;1AR) plays a crucial role in the pathogenesis of heart failure; however, underlying mechanisms remain to be elucidated. The regulation by transcription factors cAMP response element-binding protein (CREB) and cyclic AMP response element modulator (CREM) represents a fundamental mechanism of cyclic AMP–dependent gene control possibly implicated in &bgr;1AR-mediated cardiac deterioration. Methods and Results— We studied the role of CREM in &bgr;1AR-mediated cardiac effects, comparing transgenic mice with heart-directed expression of &bgr;1AR in the absence and presence of functional CREM. CREM inactivation protected from cardiomyocyte hypertrophy, fibrosis, and left ventricular dysfunction in &bgr;1AR-overexpressing mice. Transcriptome and proteome analysis revealed a set of predicted CREB/CREM target genes including the cardiac ryanodine receptor, tropomyosin 1&agr;, and cardiac &agr;-actin as altered on the mRNA or protein level along with the improved phenotype in CREM-deficient &bgr;1AR-transgenic hearts. Conclusions— The results imply the regulation of genes by CREM as an important mechanism of &bgr;1AR-induced cardiac damage in mice.
The FASEB Journal | 2007
Marek Matus; Geertje Lewin; Frank Stümpel; Igor B. Buchwalow; Michael D. Schneider; Günther Schütz; Wilhelm Schmitz; Frank U. Müller
The transcription factor cAMP response element (CRE)‐binding protein (CREB, Crebl) plays a critical role in regulating gene expression in response to activation of the cAMP‐dependent signaling pathway, which is implicated in the pathophysiology of heart failure. Using the Cre‐loxP system, we generated mice with a cardiomyocyte‐specific inactivation of CREB and studied in this model whether CREB is critical for cardiac function. CREB‐deficient mice were viable and displayed neither changes in cardiac morphology nor alterations of basal or isoproterenol‐stimulated left ventricular function in vivo or of important cardiac regulatory proteins. Since CREB was proposed as a negative regulator of cardiomyocyte apoptosis by enhancing the expression of the antiapoptotic protein Bcl‐2, we analyzed the fragmentation of DNA, the activity of caspases 3/7 and the expression of Bcl‐2 and did not observe any differences between CREB‐deficient and CREB‐normal hearts. Our results suggest that the presence of CREB is not critical for normal cardiac function in mice.—Matus M., Lewin G., Stumpel F., Buchwalow I. B., Schneider M. D., Schlitz G., Schmitz W., and Müller F. U. Cardiomyocyte‐specific inactivation of transcription factor CREB in mice. FASEB J. 21, 1884–1892 (2007)
American Journal of Physiology-heart and Circulatory Physiology | 2008
Nicole Brüchert; Nirmala Mavila; Peter Boknik; Hideo Baba; Larissa Fabritz; Ulrich Gergs; Uwe Kirchhefer; Paulus Kirchhof; Marek Matus; Wilhelm Schmitz; Joachim Neumann
Cardiac-specific overexpression of the catalytic subunit of protein phosphatase type 1 (PP1) in mice results in hypertrophy, depressed contractility, propensity to heart failure, and premature death. To further address the role of PP1 in heart function, PP1 mice were crossed with mice that overexpress a functional COOH-terminally truncated form of PP1 inhibitor-2 (I-2(140)). Protein phosphatase activity was increased in PP1 mice but was normalized in double transgenic (DT) mice. The maximal rates of contraction (+dP/dt) and of relaxation (-dP/dt) were reduced in catheterized PP1 mice but normalized in DT mice. Similar contractile abnormalities were observed in isolated, perfused work-performing hearts and in whole animals by means of echocardiography. The increased absolute and relative heart weights observed in PP1 mice were normalized in DT mice. Histological analyses indicated that PP1 mice had significant cardiac fibrosis, which was absent in DT mice. Furthermore, PP1 mice exhibited an age-dependent increase in mortality, which was abrogated in DT mice. These results indicate that I-2 overexpression prevents the detrimental effects of PP1 overexpression in the heart and further underscore the fundamental role of PP1 in cardiac function. Therefore, PP1 inhibitors such as I-2 could offer new therapeutic options to ameliorate the deleterious effects of heart failure.
Journal of the American Heart Association | 2016
Petra Keul; Marcel M. G. J. van Borren; Alexander Ghanem; Frank U. Müller; Antonius Baartscheer; Arie O. Verkerk; Frank Stümpel; Jan S. Schulte; Nazha Hamdani; Wolfgang A. Linke; Pieter B. van Loenen; Marek Matus; Wilhelm Schmitz; Jörg Stypmann; Klaus Tiemann; J. H. Ravesloot; Astrid E. Alewijnse; Sven Hermann; Léon J. A. Spijkers; Karl-Heinz Hiller; Deron R. Herr; Gerd Heusch; Michael Schäfers; Stephan L. M. Peters; Jerold Chun; Bodo Levkau
Background Sphingosine‐1‐phosphate plays vital roles in cardiomyocyte physiology, myocardial ischemia–reperfusion injury, and ischemic preconditioning. The function of the cardiomyocyte sphingosine‐1‐phosphate receptor 1 (S1P1) in vivo is unknown. Methods and Results Cardiomyocyte‐restricted deletion of S1P1 in mice (S1P1 α MHCC re) resulted in progressive cardiomyopathy, compromised response to dobutamine, and premature death. Isolated cardiomyocytes from S1P1 α MHCC re mice revealed reduced diastolic and systolic Ca2+ concentrations that were secondary to reduced intracellular Na+ and caused by suppressed activity of the sarcolemmal Na+/H+ exchanger NHE‐1 in the absence of S1P1. This scenario was successfully reproduced in wild‐type cardiomyocytes by pharmacological inhibition of S1P1 or sphingosine kinases. Furthermore, Sarcomere shortening of S1P1 α MHCC re cardiomyocytes was intact, but sarcomere relaxation was attenuated and Ca2+ sensitivity increased, respectively. This went along with reduced phosphorylation of regulatory myofilament proteins such as myosin light chain 2, myosin‐binding protein C, and troponin I. In addition, S1P1 mediated the inhibitory effect of exogenous sphingosine‐1‐phosphate on β‐adrenergic–induced cardiomyocyte contractility by inhibiting the adenylate cyclase. Furthermore, ischemic precondtioning was abolished in S1P1 α MHCC re mice and was accompanied by defective Akt activation during preconditioning. Conclusions Tonic S1P1 signaling by endogenous sphingosine‐1‐phosphate contributes to intracellular Ca2+ homeostasis by maintaining basal NHE‐1 activity and controls simultaneously myofibril Ca2+ sensitivity through its inhibitory effect on adenylate cyclase. Cardioprotection by ischemic precondtioning depends on intact S1P1 signaling. These key findings on S1P1 functions in cardiac physiology may offer novel therapeutic approaches to cardiac diseases.
American Journal of Physiology-heart and Circulatory Physiology | 2012
Dana Kucerova; Hideo Baba; Peter Boknik; Larissa Fabritz; Alexander Heinick; Marek Matus; Frank U. Müller; Joachim Neumann; Wilhelm Schmitz; Uwe Kirchhefer
Calsequestrin (CSQ) is a Ca(2+) storage protein that interacts with triadin (TRN), the ryanodine receptor (RyR), and junctin (JUN) to form a macromolecular tetrameric Ca(2+) signaling complex in the cardiac junctional sarcoplasmic reticulum (SR). Heart-specific overexpression of CSQ in transgenic mice (TG(CSQ)) was associated with heart failure, attenuation of SR Ca(2+) release, and downregulation of associated junctional SR proteins, e.g., TRN. Hence, we tested whether co-overexpression of CSQ and TRN in mouse hearts (TG(CxT)) could be beneficial for impaired intracellular Ca(2+) signaling and contractile function. Indeed, the depressed intracellular Ca(2+) concentration ([Ca](i)) peak amplitude in TG(CSQ) was normalized by co-overexpression in TG(CxT) myocytes. This effect was associated with changes in the expression of cardiac Ca(2+) regulatory proteins. For example, the protein level of the L-type Ca(2+) channel Ca(v)1.2 was higher in TG(CxT) compared with TG(CSQ). Sarco(endo)plasmic reticulum Ca(2+)-ATPase 2a (SERCA2a) expression was reduced in TG(CxT) compared with TG(CSQ), whereas JUN expression and [(3)H]ryanodine binding were lower in both TG(CxT) and TG(CSQ) compared with wild-type hearts. As a result of these expressional changes, the SR Ca(2+) load was higher in both TG(CxT) and TG(CSQ) myocytes. In contrast to the improved cellular Ca(2+), transient co-overexpression of CSQ and TRN resulted in a reduced survival rate, an increased cardiac fibrosis, and a decreased basal contractility in catheterized mice, working heart preparations, and isolated myocytes. Echocardiographic and hemodynamic measurements revealed a depressed cardiac performance after isoproterenol application in TG(CxT) compared with TG(CSQ). Our results suggest that co-overexpression of CSQ and TRN led to a normalization of the SR Ca(2+) release compared with TG(CSQ) mice but a depressed contractile function and survival rate probably due to cardiac fibrosis, a lower SERCA2a expression, and a blunted response to β-adrenergic stimulation. Thus the TRN-to-CSQ ratio is a critical modulator of the SR Ca(2+) signaling.